Pills to treat asthma are less often prescribed than inhalers, but a British study published in the United States Wednesday suggests they work just as well and are easier for patients to manage. Researchers at Britain's University of East Anglia (UEA) followed 650 chronic asthma patients for two years, and found that drugs called leukotriene receptor antagonists (LTRAs) "managed the disease equally successfully." The drugs are commonly marketed under the brand names Singulair and Accolate. The research is published in the New England Journal of Medicine. "We hope these findings will increase the options for healthcare professionals when prescribing for this common but disruptive disease," said lead author David Price of the University of Aberdeen and UEA. "We found that adherence to treatment was vastly improved by as much as 60 % when patients were given the once-a-day LTRA tablets and patients did not have to worry about using appropriate inhaler technique." In Britain, the pills are typically recommended as a third or fourth step in asthma management, and are "far less frequently prescribed than inhalers," the study noted. Asthma is a chronic breathing disease that affects 300 million people worldwide. There is no cure, but it can be often managed with medication. The government-sponsored randomized controlled trial, known as ELEVATE, gathered data from unpaid volunteer patients in 53 doctors offices across Britain.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkillerMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor